AURORA, ON–(Marketwired – Jun 22, 2015) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP)
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRES OR DISSEMINATION IN THE UNITED STATES
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the thirteenth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002″).
The trial steering committee for LDOS002 has reviewed the safety data for the twelfth cohort and recommended that Helix begin enrollment of patients into the thirteenth cohort of LDOS002 as no dose limiting toxicities were observed.
Source: www.marketwired.com
The post Aurora Based Helix BioPharma Corp. Initiates Enrollment for Thirteenth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 appeared first on Toronto Area's Tech Hub.